Interleukin-6 and insulin sensitivity: Friend or foe?

Diabetologia

Volumn 47, Issue 7, 2004, Pages 1135-1142

  Carey, A L ^a   Febbraio, M A ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

Adipocyte; Cytokines; Glucose transport; Hepatic; Insulin resistance; Skeletal muscle

Indexed keywords

INTERLEUKIN 6;

CYTOKINE PRODUCTION; CYTOKINE RELEASE; GLUCOSE TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 4143148710     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1447-y     Document Type: Review

References (95)

1. Vilcek J (1998) The cytokines: an overview. In: Thompson A (ed) The cytokine handbook. Academic Press, San Diego, pp 1-20
2. Dinarello CA, Mier JW (1986) Interleukins. Annu Rev Med 37:173-178
3. Feingold KR, Grunfeld C (1992) Role of cytokines in inducing hyperlipidemia. Diabetes 41 [Suppl 2]:97-101
4. Strassmann G, Fong M, Kenney JS, Jacob CO (1992) Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89:1681-1684
5. Campbell IL, Cutri A, Wilson A, Harrison LC (1989) Evidence for IL-6 production by and effects on the pancreatic beta-cell. J Immunol 143:1188-1191
6. Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-1292
7. Hotamisligil GS (1999) Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 107:119-125
8. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17:884-886
9. Febbraio MA, Pedersen BK (2002) Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16:1335-1347
10. Weissenbach J, Chernajovsky Y, Zeevi M et al. (1980) Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci USA 77:7152-7156
11. Hirano T, Yasukawa K, Harada H et al. (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73-76
12. Yasukawa K, Hirano T, Watanabe Y et al. (1987) Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J 6:2939-2945
13. Hirano T, Akira S, Taga T, Kishimoto T (1990) Biological and clinical aspects of interleukin 6. Immunology Today 11:443-449
14. Hirano T, Taga T, Yasukawa K et al. (1987) Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci USA 84:228-231
15. Jirik FR, Podor TJ, Hirano T et al. (1989) Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol 142:144-147
16. Stephens JM, Butts MD, Pekala PH (1992) Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by tumour necrosis factor-alpha. J Mol Endocrinol 9:61-72
17. Mohamed-Ali V, Goodrick S, Rawesh A et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196-4200
18. Penkowa M, Keller C, Keller P, Jauffred S, Pedersen BK (2003) Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise. FASEB J 17:2166-2168
19. Hiscock N, Chan MHS, Bisucci T, Darby A, Febbraio MA (2004) Skeletal myocytes are the source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J 18:992-994
20. Steensberg A, Hall G van, Osada T, Sacchetti M, Saltin B, Klarlund Pedersen B (2000) Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529:237-242
21. Taga T, Hibi M, Hirata Y et al. (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573-581
22. Mullberg J, Oberthur W, Lottspeich F et al. (1994) The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol 152:4958-4968
23. Mullberg J, Schooltink H, Stoyan T et al. (1993) The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 23:473-480
24. Zhang Y, Pilon G, Marette A, Baracos VE (2000) Cytokines and endotoxin induce cytokine receptors in skeletal muscle. Am J Physiol Endocrinol Metab 279: E196-205
25. Kami K, Morikawa Y, Sekimoto M, Senba E (2000) Gene expression of receptors for IL-6, LIF, and CNTF in regenerating skeletal muscles. J Histochem Cytochem 48:1203-1213
26. Helgren ME, Squinto SP, Davis HL et al. (1994) Trophic effect of ciliary neurotrophic factor on denervated skeletal muscle. Cell 76:493-504
27. Ishihara K, Hirano T (2002) Molecular basis of the cell specificity of cytokine action. Biochim Biophys Acta 1592:281-296
28. Jones SA, Rose-John S (2002) The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochem Biophys Acta 1592:251-263
29. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334:297-314
30. Starr R, Willson TA, Viney EM et al. (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387:917-921
31. Kado S, Nagase T, Nagata N (1999) Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol 36:67-72
32. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414-417
33. Bastard JP, Jardel C, Bruckert E et al. (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85:3338-3342
34. Pickup JC, Chusney GD, Thomas SM, Burt D (2000) Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 67:291-300
35. Starkie RL, Rolland J, Angus DJ, Anderson MJ, Febbraio MA (2001) Circulating monocytes are not the source of elevations in plasma IL-6 and TNF-alpha levels after prolonged running. Am J Physiol Cell Physiol 280:C769-C774
36. Starkie RL, Angus DJ, Rolland J, Hargreaves M, Febbraio MA (2000) Effect of prolonged, submaximal exercise and carbohydrate ingestion on monocyte intracellular cytokine production in humans. J Physiol 528:647-655
37. Steensberg A, Fischer CP, Sacchetti M et al. (2003) Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548:631-638
38. Hall G van, Steenberg A, Sacchetti M et al. (2003) Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005-3010
39. Steensberg A, Febbraio MA, Osada T et al. (2001) Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol 537:633-639
40. Liao J, Keiser JA, Scales WE, Kunkel SL, Kluger MJ (1995) Role of corticosterone in TNF and IL-6 production in isolated perfused rat liver. Am J Physiol Regul Integr Comp Physiol 268:R699-R706
41. Liao J, Keiser JA, Scales WE, Kunkel SL, Kluger MJ (1995) Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am J Physiol Regul Integr Comp Physiol 268:R896-R901
42. Iwai M, Cui TX, Kitamura H, Saito M, Shimazu T (2001) Increased secretion of tumour necrosis factor and interleukin 6 from isolated, perfused liver of rats after partial hepatectomy. Cytokine 13:60-64
43. Rumbaugh KP, Colmer JA, Griswold JA, Hamood AN (2001) The effects of infection of thermal injury by Pseudomonas aeruginosa PAO1 on the murine cytokine response. Cytokine 16:160-168
44. Nadler EP, Dickinson EC, Beer-Stolz D et al. (2001) Scavenging nitric oxide reduces hepatocellular injury after endotoxin challenge. Am J Physiol Gastrointest Liver Physiol 281:G173-G181
45. Watchorn TM, Waddell I, Dowidar N, Ross JA (2001) Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB J 15:562-564
46. Febbraio MA, Ott P, Nielsen HB et al. (2003) Hepatos-planchnic clearance of interleukin-6 in humans during exercise. Am J Physiol Endocrinol Metab 285:E397-402
47. Carey AL, Bruce CR, Sacchetti M et al. (2004) Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47:1029-1037
48. Keller P, Keller C, Carey AL et al. (2003) Interleukin-6 production by contracting human skeletal muscle: autocrine regulation by IL-6. Biochem Biophys Res Commun 310:550-554
49. Fasshauer M, Klein J, Lossner U, Paschke R (2003) Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor alpha, growth hormone, and IL-6 in 3T3-L1 adipocytes. Horm Metab Res 35:147-152
50. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91
51. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM (1994) Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 94:1543-1549
52. Neta R, Sayers TJ, Oppenheim JJ (1992) Relationship of TNF to interleukins. Immunol Ser 56:499-566
53. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334
54. Makino T, Noguchi Y, Yoshikawa T, Doi C, Nomura K (1998) Circulating interleukin 6 concentrations and insulin resistance in patients with cancer. Br J Surg 85:1658-1662
55. Rotter V, Nagaev I, Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and TNFalpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777-45785
56. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745-751
57. Bastard JP, Maachi M, Van Nhieu JT et al. (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87:2084-2089
58. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J (1985) Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 76:149-155
59. Carey AL, Lamont B, Andrikopoulos S, Koukoulas I, Proietto J, Febbraio MA (2003) Interleukin-6 gene expression is increased in insulin-resistant rat skeletal muscle following insulin stimulation. Biochem Biophys Res Commun 302:837-840
60. Febbraio MA, Steensberg A, Starkie RL, McConell GK, Kingwell BA (2003) Skeletal muscle interleukin-6 and tumor necrosis factor-alpha release in healthy subjects and patients with type 2 diabetes at rest and during exercise. Metabolism 52:939-944
61. Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391-3399
62. Senn JJ, Klover PJ, Nowak IA et al. (2003) Suppressor of Cytokine Signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278:13740-13746
63. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M (2003) Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311:372-379
64. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784-2789
65. Lee MD, Zentella A, Vine W, Pekala PH, Cerami A (1987) Effect of endotoxin-induced monokines on glucose metabolism in the muscle cell line L6. Proc Natl Acad Sci USA 84:2590-2594
66. Stouthard JM, Oude Elferink RP, Sauerwein HP (1996) Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes. Biochem Biophys Res Comm 220:241-245
67. Hardin J, Kroeker K, Chung B, Gall DG (2000) Effect of proinflammatory interleukins on jejunal nutrient transport. Gut 47:184-191
68. Shikhman AR, Brinson DC, Valbracht J, Lotz MK (2001) Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J Immunol 167:7001-7008
69. Huppertz C, Schwartz C, Becker W, Horn F, Heinrich PC, Joost HG (1996) Comparison of the effects of insulin, PDGF, interleukin-6, and interferon-gamma on glucose transport in 3T3-L1 cells: lack of cross-talk between tyrosine kinase receptors and JAK/STAT pathways. Diabetologia 39:1432-1439
70. Fasshauer M, Kralisch S, Klier M et al. (2003) Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301:1045-1050
71. Wei LH, Kuo ML, Chen CA et al. (2001) The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 20:5799-5809
72. Jee SH, Chiu HC, Tsai TF et al. (2002) The phosphotidyl inositol 3-kinase/Akt signal pathway is involved in interleukin-6-mediated Mcl-1 upregulation and anti-apoptosis activity in basal cell carcinoma cells. J Invest Dermatol 119:1121-1127
73. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML (1999) Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem 274:23013-23019
74. Kanemaki T, Kitade H, Kaibori M et al. (1998) Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 27:1296-1303
75. Dietze D, Koenen M, Rohrig K, Horikoshi H, Hauner H, Eckel J (2002) Impairment of insulin signaling in human skeletal muscle cells by co-culture with human adipocytes. Diabetes 51:2369-2376
76. Fernandez-Real JM, Broch M, Vendrell J et al. (2000) Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49:517-520
77. Kubaszek A, Pihlajamaki J, Komarovski V et al. (2003) Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52:1872-1876
78. Vozarova B, Fernandez-Real JM, Knowler WC et al. (2003) The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 112:409-413
79. Stouthard JM, Romijn JA, Van der Poll T et al. (1995) Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol Endocrinol Metab 268:E813-E819
80. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP (1997) Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82:4167-4170
81. Lyngso D, Simonsen L, Bulow J (2002) Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol 543:379-386
82. Wallenius V, Wallenius K, Ahren B et al. (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75-79
83. Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO (2002) Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 293:560-565
84. Hill M, McCallum R (1991) Altered transcriptional regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment. J Clin Invest 88:811-816
85. Christ B, Nath A, Heinrich PC, Jungermann K (1994) Inhibition by recombinant human interleukin-6 of the glucagon-dependent induction of phosphoenolpyruvate carboxy-kinase and of the insulin-dependent induction of glucokinase gene expression in cultured rat hepatocytes: regulation of gene transcription and messenger RNA degradation. Hepatology 20:1577-1583
86. Nonogaki K, Fuller GM, Fuentes NL et al. (1995) Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 136:2143-2149
87. Stith RD, Luo J (1994) Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock 44:210-215
88. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK (2004) Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53:1643-1648
89. Deviere J, Content J, Denys C et al. (1989) High interleukin-6 serum levels and increased production by leucocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines production. Clin Exp Immunol 77:221-225
90. Andus T, Bauer J, Gerok W (1991) Effects of cytokines on the liver. Hepatology 13:364-375
91. Dovio A, Angeli A (2001) Cytokines and type 2 diabetes mellitus. JAMA 286:2233
92. Dovio A, Masera RG, Sartori ML, Racca S, Angeli A (2001) Autocrine up-regulation of glucocorticoid receptors by interleukin-6 in human osteoblast-like cells. Calcif Tissue Int 69:293-298
93. Takano A, Usui I, Haruta T et al. (2001) Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 21:5050-5062
94. Tremblay F, Marette A (2001) Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 276:38052-38060
95. Gual P, Gremeaux T, Gonzalez T, Le Marchand-Brustel Y, Tanti JF (2003) MAP kinases and mTOR mediate insulin-induced phosphorylation of Insulin Receptor Substrate-1 on serine residues 307, 612 and 632. Diabetologia 46:1532-1542